Brennand, Kristen J.Marchetto, M. CarolBenvenisty, NissimBrüstle, OliverEbert, AllisonIzpisua Belmonte, Juan CarlosKaykas, AjameteLancaster, Madeline A.Livesey, Frederick J.McConnell, Michael J.McKay, Ronald D.Morrow, Eric M.Muotri, Alysson R.Panchision, David M.Rubin, Lee L.Sawa, AkiraSoldner, FrankSong, HongjunStuder, LorenzTemple, SallyVaccarino, Flora M.Wu, JunVanderhaeghen, PierreGage, Fred H.Jaenisch, Rudolf2016-07-142015Brennand, K., M. Marchetto, N. Benvenisty, O. Brüstle, A. Ebert, J. Izpisua Belmonte, A. Kaykas, et al. 2015. “Creating Patient-Specific Neural Cells for the In Vitro Study of Brain Disorders.” Stem Cell Reports 5 (6): 933-945. doi:10.1016/j.stemcr.2015.10.011. http://dx.doi.org/10.1016/j.stemcr.2015.10.011.2213-6711http://nrs.harvard.edu/urn-3:HUL.InstRepos:27662269Summary As a group, we met to discuss the current challenges for creating meaningful patient-specific in vitro models to study brain disorders. Although the convergence of findings between laboratories and patient cohorts provided us confidence and optimism that hiPSC-based platforms will inform future drug discovery efforts, a number of critical technical challenges remain. This opinion piece outlines our collective views on the current state of hiPSC-based disease modeling and discusses what we see to be the critical objectives that must be addressed collectively as a field.en-USJournal Article2016-07-1410.1016/j.stemcr.2015.10.011